Get the Stockscreener App
2.65
5.36%
-0.15
After Hours:
2.78
0.13
+4.91%
Aquestive Therapeutics Inc stock is traded at $2.65, with a volume of 928.07K.
It is down -5.36% in the last 24 hours and down -8.30% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
See More
Previous Close:
$2.80
Open:
$2.83
24h Volume:
928.07K
Relative Volume:
0.57
Market Cap:
$250.74M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-7.2782
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
-10.47%
1M Performance:
-8.30%
6M Performance:
-36.75%
1Y Performance:
-37.50%
1-Day Range:
$2.62
$2.855
1-Week Range:
$2.62
$2.99
52-Week Range:
$2.24
$6.23
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
2.65 | 250.74M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
170.53 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.58 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.84 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.00 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.28 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Wednesday - Defense World
Aquestive Therapeutics (AQST) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Aquestive Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March - The Manila Times
Aquestive Therapeutics Sets March Conference Schedule: Key Dates for Investor Access - StockTitan
Aquestive Therapeutics' SWOT analysis: PharmFilm tech could disrupt epinephrine stock By Investing.com - Investing.com South Africa
Aquestive Therapeutics' SWOT analysis: PharmFilm tech could disrupt epinephrine stock - Investing.com India
Aquestive Therapeutics’ SWOT analysis: PharmFilm tech could disrupt epinephrine stock - Investing.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update - MarketBeat
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET - The Manila Times
Aquestive Therapeutics to Report Fourth Quarter 2024 - GlobeNewswire
Aquestive Therapeutics Q4 Earnings: Will New Business Updates Signal Growth Momentum? - StockTitan
Leerink maintains Aquestive Outperform rating, $13 target By Investing.com - Investing.com Canada
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Drop in Short Interest - Defense World
JMP Securities maintains $9 target on Aquestive Therapeutics stock By Investing.com - Investing.com Australia
Harvey Capital Management Inc. Buys 249,790 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $11.00 - MarketBeat
Aquestive Therapeutics Inc (NASDAQ: AQST) Is A Blank Check For Growth - Stocks Register
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week - Simply Wall St
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $11.00 Consensus Price Target from Analysts - MarketBeat
Aquestive Therapeutics to Present New Findings on Anaphylm™ - GlobeNewswire
Aquestive Therapeutics Announces Positive Stability and Efficacy Data for Anaphylm Epinephrine Sublingual Film at AAAAI Annual Meeting - Nasdaq
Breakthrough Allergy Treatment Shows 12-Min Response Time: Aquestive's Game-Changing Phase 2 Results - StockTitan
SG Americas Securities LLC Grows Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Wall Street analysts’ outlook for Aquestive Therapeutics Inc (AQST) - SETE News
Aquestive Therapeutics Inc [AQST] stock for 214 USD was sold by Jung Cassie - Knox Daily
Aquestive Therapeutics Inc (AQST) expanding its growth trajectory ahead - SETE News
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Significant Increase in Short Interest - MarketBeat
Epilepsy Market Expected to rise, 2034 | Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven - Barchart
Did Aquestive Therapeutics Inc (AQST) perform well in the last session? - US Post News
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference - GlobeNewswire
Piper starts Aquestive at overweight, cites allergy reaction treatment - MSN
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates - MSN
Institutional investors own a significant stake of 49% in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Yahoo Finance
Cantor Fitzgerald Weighs in on AQST FY2025 Earnings - MarketBeat
Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Up 8.6% in December - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Barclays PLC - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Anaphylaxis Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight | Aravax Pty Ltd, AstraZeneca, Aquestive Therapeutics - Barchart
Neuromuscular Disease Therapeutics Market to grow by USD 13.7 Billion from 2025-2029, driven by novel approvals, with AI impacting market trendsTechnavio - The Malaysian Reserve
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Aquestive Therapeutics Updates on Strategic Goals and Drug Progress - TipRanks
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schobel Alexander Mark | Chief Innovation/Tech Officer |
Mar 15 '24 |
Sale |
6.00 |
50,000 |
300,000 |
984,476 |
| Schobel Alexander Mark | Chief Innovation/Tech Officer |
Mar 08 '24 |
Sale |
5.19 |
25,000 |
129,685 |
1,040,371 |
1.25%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):